The soaring share price of Aba Chemicals Corporation(300261) is the latest case of “value discovery” of a shares? Or illegal operation under the cover of speculative enthusiasm?
Recently, due to the suspected “hot spot” of covid-19 oral medicine, Aba Chemicals Corporation(300261) share price rose sharply in the short term. In this regard, the company announced that it denied direct supply and said that there was no change in supply and demand in the downstream market. But these statements did not extinguish the enthusiasm of market speculation.
When things go wrong, there will be demons. Just as the share price soared, Wang Xinya, one of the actual controllers of Aba Chemicals Corporation(300261) , began to reduce his holdings at a high level. On November 30, he reduced his holdings of 19 million shares, accounting for 1.97% of the total share capital, and the average reduction price was 7.24 yuan / share, cashing out 138 million yuan.
Regulators have noticed the “story” of Aba Chemicals Corporation(300261) , and regulatory inquiry letters point directly at the suspicious points behind the company’s information disclosure and stock price changes.
just now, Aba Chemicals Corporation(300261) issued an announcement: stock trading is seriously abnormal, and the trading is suspended for verification.
deny that it is difficult to stop the soaring share price
On December 28, Aba Chemicals Corporation(300261) rose strongly again. As of the closing of the day, Aba Chemicals Corporation(300261) “20cm” trading limit was reported at 19.16 yuan.
On the evening of the previous day (the 27th), Aba Chemicals Corporation(300261) announced that the company’s share price rose significantly in the short term, but there was no significant change in production and operation. The company reminds investors to pay attention to the transaction risks in the secondary market, make rational decisions and invest prudently.
The company said that it was concerned about the high attention of investors on the interactive platform to the company’s carbonic anhydride and its derivatives recently, and made the following clarifications and risk tips for the relevant situation: as of the disclosure date of the announcement, the company had not signed any cooperation agreement with Pfizer, had no cooperative relationship with Pfizer, and did not supply carbonic anhydride and its derivatives to Pfizer.
The customers of the company’s carbonic anhydride and its derivatives are mainly Chinese customers and Indian customers. It is uncertain whether the company’s carbonic anhydride and its derivatives are indirectly supplied to Pfizer. The sales revenue of company’s carbonic anhydride and its derivatives accounted for about 0.5% – 2% of the company’s total operating revenue this year, accounting for a relatively small proportion, which will not have a significant impact on the company’s performance.
From the extended time line, the share price of Aba Chemicals Corporation(300261) has not improved before this round of sharp rise, hovering all the way from the closing price of 6.27 yuan / share at the beginning of the year to 5.13 yuan / share on October 29.
After November 5, the company’s share price began to “agitate”, and recently got on the “helicopter”. As of press time, the company’s share price has risen 159.62% in the last seven trading days. Since November 5, the company’s share price has risen 267.75%.
After a long silence, Aba Chemicals Corporation(300261) suddenly won the “favor” of the market for two reasons: first, the company will produce cannabinol (CBD) and tetrahydrocannabinol (THC) extracts; Second, the market is optimistic about its carbonic anhydride products.
For the first question, the company disclosed a supplementary announcement on stock trading changes after hours on the 24th, saying that up to now, the company’s CBD products have not been put into production due to the impact of the European epidemic, and the production of relevant products will be postponed to 2023.
As for the second reason, Aba Chemicals Corporation(300261) replied many times in the announcement that did not directly sign any cooperation agreement with Pfizer, there was no direct cooperation relationship, and did not directly supply carlon anhydride products to Pfizer. The company also suggested that “there has been no significant change in the downstream market demand of the company’s industry, main business and main products recently. The company respectfully asks investors to pay attention to investment risks.”
Pfizer’s “suspected supplier” of oral covid-19
On December 22 local time, the US Food and Drug Administration (FDA) approved Pfizer’s covid-19 oral drug paxlovid. According to the FDA Statement, each dose of oral covid-19 paxlovid consists of two antiviral drugs “nirmatrelvir” and one ritonavir. According to the clinical trial data released by Pfizer on December 14, paxlovid is 89% effective in preventing hospitalization and death of severe and high-risk patients.
Paxlovid is a compound preparation of 3CL protease inhibitor pf-07321332 (hereinafter referred to as “pf”) and low-dose ritonavir. In a report released on China International Capital Corporation Limited(601995) December 5, it focuses on the intermediate of synthesizing PF, carbonic anhydride, and it can not be bypassed either by inulin route or isopentenol route. Carbonic anhydride is considered by the market as “the most directly beneficial intermediate due to Pfizer’s oral specific drugs”.
because of this, this round of “treasure hunt” has become to find the supplier most likely to supply Pfizer with carbonic anhydride.
It is worth noting that on November 4, Aba Chemicals Corporation(300261) revealed on its official website that the commercialization and mass production of the pharmaceutical intermediate carbonic anhydride developed and produced by the company is smooth, and the monthly production scale has reached 20 tons.
As a competitor of Aba Chemicals Corporation(300261) , Zhejiang Jianfeng Group Co.Ltd(600668) is also speculated by the market as a raw material supplier of MSD and Pfizer because it has patents for uridine and carbonic anhydride at the same time.
Previously, China’s contract customized R & D and production (cdmo) listed companies Asymchem Laboratories (Tianjin) Co.Ltd(002821) and Porton Pharma Solutions Ltd(300363) successively issued announcements in November. Although the confidentiality agreement does not directly refer to the partners of major agreements, the contract amount is high and it is a small molecule innovative drug. Combined with the intensive time point of announcement, many people in the industry speculate that it may provide cdmo services for paxlovid. Piaoyi chemical, a subsidiary of Aba Chemicals Corporation(300261) , previously supplied intermediates to Porton Pharma Solutions Ltd(300363) .
Therefore, Aba Chemicals Corporation(300261) has attracted extensive attention from capital in the secondary market.
To promote the rise of a company’s price, we must have a catalyst, which is the realistic objective demand. In fact, does Aba Chemicals Corporation(300261) carbonic anhydride really indirectly become the source of raw material supply for paxlovid? How much market can paxlovid reach in the future? It is not known at present.
Tao Lina, a Chinese vaccine researcher, previously publicly said that the market was too optimistic about covid-19 oral medicine. He said that the primary task of combating covid-19 virus is to rely on vaccination and support treatment.
But what is the reason why the market chose Aba Chemicals Corporation(300261) despite the information gap?
Some investment bankers told reporters that first of all, Aba Chemicals Corporation(300261) company has a small market value and is easy to rise; At the same time, there is information related to the Caron anhydride product “Pfizer covid-19 oral drug”, and the secondary market pays high attention to the topic, which can attract a large influx of funds.
high position reduction of letter Phi violation actual controller
It should be noted that Aba Chemicals Corporation(300261) fell on the hot spot of “covid-19 drug”.
In addition to the direct inducement of this round of soaring “carbonic anhydride”, previously Aba Chemicals Corporation(300261) has repeatedly said on the investor interaction platform that the subsidiary Piaoyi chemical is the main supplier of key intermediates of azanavir and darunavir. According to public data, the research results of Academician Li Lanjuan’s team confirmed that “abidol and darunavir can effectively inhibit coronavirus”.
It is precisely because Aba Chemicals Corporation(300261) received the decision on administrative punishment issued by the CSRC because of the remarks of the “covid-19” drug intermediate supplier disclosed on the interactive platform and the illegal disclosure of information such as misleading statements. According to the investigation of the CSRC, Aba Chemicals Corporation(300261) falsely increased revenue and fictitious customers in the pharmaceutical intermediate business of dalunavir. In this regard, the CSRC decided to give a warning to Aba Chemicals Corporation(300261) and impose a fine of 400000 yuan; The then chairman and others were given a warning and fined a total of 350000 yuan.
in addition, it can not be ignored that while the company’s share price is rising, the actual controller began to reduce the company’s shares at a high level.
According to the announcement on December 1, Aba Chemicals Corporation(300261) Wang Xinya, one of the actual controllers, reduced his holdings of 19 million shares through block trading on November 30, accounting for 1.97% of the total share capital of the company. The average reduction price was 7.24 yuan / share, with a total cash out of 138 million yuan.
If Pfizer had signed a contract with relevant cdmo companies in November and Aba Chemicals Corporation(300261) was really its raw material supplier, would it be logical for the company’s actual controller to resolutely give up such a high proportion of the company’s shares at this moment?
what can not be ignored is that accompanied by the sharp rise of share price, some we media frequently publish stock recommendation articles advocating Aba Chemicals Corporation(300261) competitiveness in Caron anhydride on the network platform. Are the authors of these articles and the related parties behind them secretly related to the stock price change of Aba Chemicals Corporation(300261) ? Regulators may further conduct thorough investigation through background big data.
(Shanghai Securities News)
